Acetyl-L-Carnitine for Male Infertility

Verdict: Helps sperm motility; pregnancy benefit unproven

Acetyl-L-carnitine (usually as part of a carnitine blend) reliably improves surrogate sperm measures like motility and morphology, but there is no convincing evidence it raises pregnancy or live-birth rates on its own. It rates as preliminary (Tier B) evidence and is published with a warning.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Four meta-analyses and a randomized trial consistently show carnitine improves sperm parameters. A 2025 network meta-analysis ranked L-carnitine first for progressive motility (SMD 4.19, PMID 40813743), a 2025 monotherapy meta-analysis found gains in concentration, morphology, motility and testosterone (PMID 40350672), and a 175-man double-blind RCT improved progressive motility, vitality and DNA fragmentation (PMID 30873633). This replicated surrogate benefit is what earns a B rather than a fail.

The grade stops at B because the outcomes that actually matter, pregnancy and live birth, are weak and combination-dependent. Pregnancy benefit appears mainly for L-carnitine plus micronutrients (RR 3.60, PMID 36943634) or in an older, lower-quality review (OR 4.10, PMID 17392136), and live birth is essentially unstudied. Because acetyl-L-carnitine is almost always tested inside blends like Proxeed Plus, its stand-alone effect is uncertain.

Authorities are unsupportive or silent, which holds the score down. The US FDA classifies carnitine only as a nutrient supplement with no fertility claim, the EU EFSA rejected carnitine health claims, the WHO does not list it as essential, and Mayo Clinic plus the AUA/ASRM specialty guidance call fertility supplements of questionable clinical value.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.633
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review
PMID: 17392136 2007 統合分析
Finding: Across 9 RCTs, LC and/or LAC significantly improved pregnancy rate (OR 4.10, 95% CI 2.08 to 8.08, p<0.0001), total sperm motility (WMD +7.43, 95% CI 1.72 to 13.14, p=0.04), forward sperm motility (WMD +11.83, 95% CI 0.49 to 23.16, p=0.04), and reduced atypical sperm cells (WMD -5.72, 95% CI -7.89 to -3.56, p<0.00001).
🟠 Limited quality Effect size: Pregnancy OR 4.10; total motility WMD +7.43; forward motility WMD +11.83
View on PubMed
Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia
PMID: 30873633 2019 RCT (double-blind) n = 175
Finding: In 175 men with idiopathic oligoasthenozoospermia, sperm volume, progressive motility and vitality significantly improved (p<0.001) after 6 months versus baseline, and DNA fragmentation index decreased at 6 months; seminal carnitine concentration correlated positively with improved progressive motility. Pregnancy was not the reported endpoint.
Effect size: Progressive motility and vitality significant improvement at 6 months (p<0.001)
View on PubMed
Effectiveness of Nutritional Therapies in Male Factor Infertility Treatment: A Systematic Review and Network Meta-analysis
PMID: 36943634 2023 Network Meta-analysis
Finding: L-carnitine combined with micronutrients significantly improved pregnancy rate (RR 3.60, 95% CI 1.86 to 6.98, p=0.0002) and ranked among the most effective nutritional therapies for sperm quality; meta-regression linked sperm parameter improvement to higher pregnancy rates, with oligozoospermic men benefiting most (RR 4.89).
Government Effect size: Pregnancy RR 3.60 (L-carnitine + micronutrients)
View on PubMed
Meta-analysis of the efficacy and safety of L-carnitine and N-acetylcysteine monotherapy for male idiopathic infertility
PMID: 40350672 2025 統合分析
Finding: L-carnitine monotherapy significantly increased sperm concentration (p<0.001), improved normal morphology (p=0.03), enhanced motility (p=0.02), and raised testosterone (p<0.001) in men with idiopathic infertility; safety profile favorable. Pregnancy or live birth was not the primary endpoint.
Government Effect size: Significant gains in concentration, morphology, motility and testosterone (semen-parameter endpoints)
View on PubMed
Effects of Carnitine and Coenzyme Q10 on Sperm Quality and Pregnancy Rates in Men with Unexplained Infertility: A Systematic Review and Network Meta-Analysis
PMID: 40813743 2025 Network Meta-analysis
Finding: L-carnitine produced the greatest improvement in progressive sperm motility (SMD 4.19, 95% CI 1.60 to 10.95) and was ranked the best treatment for sperm motility, while CoQ10 ranked highest for concentration; the network analysis identified carnitine as a leading antioxidant for motility outcomes.
Government Effect size: Progressive motility SMD 4.19 (L-carnitine, ranked first)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
NUTRIENT SUPPLEMENT [21 CFR 170.3(o) technical effect — substance: Carnitine / L-carnitine / Levocarnitine, CAS 541-15-1] source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,L-肉鹼(L-carnitine)總含量不得高於 2 公克。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-male-infertility-INT-acetyl-l-carnitine-001 繁體中文版 →